Roche projects mid-single digit group sales growth in 2025, with core EPS growth in the high-single digit range. The company expects a CHF1.2 billion impact from the loss of exclusivity but aims to ...
Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...
In this instance, the partnership will combine Senseonics’ Eversense continuous glucose monitor (CGM), TypeZero’s InControl algorithms, and Roche’s Accu-Chek Insight Insulin Pump.
Robust investment flows, resilient Asian consumer demand and relentless central-bank purchases look set to offset any potential headwinds from a hawkish shift in U.S. monetary policy and with the ...
Last year, Novo Nordisk also signed a deal with the CGM specialist – as well as mobile app company Glooko and Roche’s diagnostics division – to develop connected insulin pens. “CGMs ...
With a solid foundation for growth and a promising outlook, the global lancet market is on track to achieve its projected USD ...
He is a member of a number of advisory boards for companies developing novel diagnostic and therapeutic options for diabetes therapy, including Roche Diagnostics, Sanofi, Abbott, and Medtronic.
For that reason, while it’s possible, we’ll see the feature introduced in some form in the Galaxy Watch … it wouldn’t be surprising if the holy grail of continuous glucose monitoring slips ...
Nature Research Intelligence Topics enable transformational understanding and discovery in research by categorising any document into meaningful, accessible topics. Read this blog to understand ...
Advances such as miniaturized, transportable diagnostic devices, which present laboratory-quality findings outside of health care settings, represent a leading technological shift within the point ...